A phase 1b open label study of safety and tolerability in patients treated with stereotactic radiotherapy (to the primary tumor) combined with durvalumab (MEDI4736) and tremelimumab in patients with stage 4 non-small cell lung cancer

Trial Profile

A phase 1b open label study of safety and tolerability in patients treated with stereotactic radiotherapy (to the primary tumor) combined with durvalumab (MEDI4736) and tremelimumab in patients with stage 4 non-small cell lung cancer

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top